Skip to main content
SpringerLink
Log in
Book cover

MicroRNAs and Other Non-Coding RNAs in Inflammation pp 219–230Cite as

ncRNA as Diagnostics and Prognostics for Hepatocellular Carcinoma

  • Chapter
  • First Online:

  • 1005 Accesses

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the sixth most common cancer in the world with an estimated over half a million new cases annually. Due to the difficulty in early diagnosis, poor prognosis and lack of effective treatment options, HCC is currently ranked as the second most common neoplastic-related death with a significantly low 5-year survival rate of 6–11 % worldwide. Non-coding RNAs (ncRNAs) are genes that are frequently transcribed without protein-coding ability. Two major subsets of ncRNAs, microRNAs (miRNA) and long non-coding RNAs (lncRNA), are considered essential components at multiple levels in gene regulation processes including transcription, post-transcription and translation. The aberrant expression of ncRNAs has been shown to play an important role in many diseases including HCC. ncRNAs are abundant and stable; these fundamental characteristics make them candidates as diagnostic and prognostic biomarkers with wide reaching potential. Here we review the current status of diagnostic, prognostic and therapeutic biomarkers for HCC.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Globocan (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012

    Google Scholar 

  2. Di Bisceglie AM (2009) Hepatitis B and hepatocellular carcinoma. Hepatology 49:S56–S60. doi:10.1002/hep.22962

    Article  PubMed Central  PubMed  Google Scholar 

  3. Di Bisceglie AM (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26:34S–38S

    Article  PubMed  Google Scholar 

  4. Zhao J, Lawless MW (2013) Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. Cytokine 64:626–637. doi:10.1016/j.cyto.2013.09.009

    Article  CAS  PubMed  Google Scholar 

  5. Morgan TR, Mandayam S, Jamal MM (2004) Alcohol and hepatocellular carcinoma. Gastroenterology 127:S87–S96

    Article  CAS  PubMed  Google Scholar 

  6. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820–1832. doi:10.1002/hep.23594

    Article  PubMed  Google Scholar 

  7. Kowdley KV (2004) Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127:S79–S86

    Article  CAS  PubMed  Google Scholar 

  8. Lawless MW (2009) Protein misfolding: a new paradigm HFE C282Y hereditary hemochromatosis. Nova, Hauppauge, NY

    Google Scholar 

  9. Gray SG, Crowe J, Lawless MW (2009) Hemochromatosis: as a conformational disorder. Int J Biochem Cell Biol 41:2094–2097. doi:10.1016/j.biocel.2009.04.006

    Article  CAS  PubMed  Google Scholar 

  10. Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 314:736–739

    Article  CAS  PubMed  Google Scholar 

  11. Greene CM, Miller SD, Carroll T, McLean C, O’Mahony M, Lawless MW et al (2008) Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations. J Inherit Metab Dis 31:21–34. doi:10.1007/s10545-007-0748-y

    Article  CAS  PubMed  Google Scholar 

  12. Lawless MW, Mankan AK, Gray SG, Norris S (2008) Endoplasmic reticulum stress—a double edged sword for Z alpha-a antitrypsin deficiency hepatoxicity. Int J Biochem Cell Biol 40:1403–1414. doi:10.1016/j.biocel.2008.02.008

    Article  CAS  PubMed  Google Scholar 

  13. Lawless MW (2009) The serine proteinase inhibitors Z alpha-1 antitrypsin: acting on the NF-kappaB system for cytotoxicity. Serpines and protein kinase inhibitors: novel functions, structural features and molecular mechanisms. Nova, Hauppauge, NY

    Google Scholar 

  14. Liu Y, Wu F (2010) Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 118:818–824. doi:10.1289/ehp.0901388

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, Aronson D et al (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Paediatric Oncology group. J Clin Oncol 20:2798–2804

    Article  CAS  PubMed  Google Scholar 

  16. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854

    Article  CAS  PubMed  Google Scholar 

  17. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75:855–862

    Article  CAS  PubMed  Google Scholar 

  18. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12:861–874. doi:10.1038/nrg3074

    Article  CAS  PubMed  Google Scholar 

  19. Wang ZL, Li XY (2013) The role of noncoding RNA in hepatocellular carcinoma. Gland Surg 2:25–29. doi:10.3978/j.issn. 2227-684X.2013.02.07

    PubMed Central  PubMed  Google Scholar 

  20. Scott MS, Ono M (2011) From snoRNA to miRNA: dual function regulatory non-coding RNAs. Biochimie 93:1987–1992. doi:10.1016/j.biochi.2011.05.026

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Ke XS, Liu CM, Liu DP, Liang CC (2003) MicroRNAs: key participants in gene regulatory networks. Curr Opin Chem Biol 7:516–523

    Article  CAS  PubMed  Google Scholar 

  22. Ha TY (2011) MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw 11:135–154. doi:10.4110/in.2011.11.3.135

    Article  PubMed Central  PubMed  Google Scholar 

  23. Lu Y, Yue X, Cui Y, Zhang J, Wang K (2013) MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun 441:873–879. doi:10.1016/j.bbrc.2013.10.157

    Article  CAS  PubMed  Google Scholar 

  24. Yau WL, Lam CS, Ng L, Chow AK, Chan ST, Chan JY et al (2013) Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process. PLoS One 8:e57882. doi:10.1371/journal.pone.0057882

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Yang H, Fang F, Chang R, Yang L (2013) MicroRNA-140-5p suppresses tumour growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58:205–217. doi:10.1002/hep.26315

    Article  CAS  PubMed  Google Scholar 

  26. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F et al (2013) Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49:1083–1096. doi:10.1016/j.molcel.2013.01.010

    Article  CAS  PubMed  Google Scholar 

  27. Greene CM, Varley RB, Lawless MW (2013) MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol 19:5212–5226. doi:10.3748/wjg.v19.i32.5212

    Article  PubMed Central  PubMed  Google Scholar 

  28. Giordano S, Columbano A (2013) MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 57:840–847. doi:10.1002/hep.26095

    Article  CAS  PubMed  Google Scholar 

  29. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198

    Article  CAS  PubMed  Google Scholar 

  30. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F et al (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126:1166–1176. doi:10.1002/ijc.24827

    CAS  PubMed  Google Scholar 

  31. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425–436. doi:10.1001/jama.299.4.425

    PubMed Central  CAS  PubMed  Google Scholar 

  32. Lee H, Park JE, Nam JM (2014) Bio-barcode gel assay for microRNA. Nat Commun 5:3367. doi:10.1038/ncomms4367

    PubMed  Google Scholar 

  33. Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L et al (2009) Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 118:2600–2608. doi:10.1172/JCI34934

    Google Scholar 

  34. Shen J, Ambrosone CB, Zhao H (2009) Novel genetic variants in microRNA genes and familial breast cancer. Int J Cancer 124:1178–1182. doi:10.1002/ijc.24008

    Article  CAS  PubMed  Google Scholar 

  35. Chen CJ (2011) Early diagnosis of hepatocellular carcinoma by multiple microRNAs: validity, efficacy, and cost-effectiveness. J Clin Oncol 29:4745–4747. doi:10.1200/JCO.2011.39.0054

    Article  CAS  PubMed  Google Scholar 

  36. Jiang JM, Gusev Y, Aderca I et al (2008) Association of microRNA expression in hepatocellular carcinoma with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14:419–427

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M (2011) Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 45:355–360. doi:10.1097/MCG.0b013e3181f18ac2

    Article  CAS  PubMed  Google Scholar 

  38. Qi P, Cheng SQ, Wang H, Li N, Chen YF et al (2011) Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 6:e28486. doi:10.1371/journal.pone.0028486

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T et al (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50:136–142. doi:10.1002/mc.20712

    Article  CAS  PubMed  Google Scholar 

  40. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y et al (2008) Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 283:13205–13215. doi:10.1047/jbc.M707629200

    Article  CAS  PubMed  Google Scholar 

  41. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezqin O et al (2014) Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. doi:10.1007/s11033-014-3322-3

    PubMed  Google Scholar 

  42. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST et al (2012) Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2:e000825. doi:10.1136/bmjopen-2012-000825

    Article  PubMed Central  PubMed  Google Scholar 

  43. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J et al (2011) Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 120:183–193. doi:10.1042/CS20100297

    Article  CAS  Google Scholar 

  44. Li T, Yin J, Yuan L, Wang S, Yang L, Du X et al (2014) Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short term survival. Oncol Rep 31:1699–1706. doi:10.3892/or.2014.3032

    CAS  PubMed  Google Scholar 

  45. Liang Z, Gao Y, Shi W, Zhai D, Li S, Jing L et al (2013) Expression and significance of microRNA-183 in hepatocellular carcinoma. ScientificWorldJournal. doi:10.1155/2013/381874

    Google Scholar 

  46. Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T et al (2009) MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14:529–538. doi:10.3109/13547500903150771

    Article  CAS  PubMed  Google Scholar 

  47. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J et al (2013) Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 49:3442–3449. doi:10.1016/j.ejca.2013.06.002

    Article  PubMed  Google Scholar 

  48. Fu Y, Wei X, Tang C, Li J, Liu R, Shen A et al (2013) Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett 6:1811–1815. doi:10.3892/ol.2013.1638

    PubMed Central  CAS  PubMed  Google Scholar 

  49. Rong M, He R, Dang Y, Chen G (2014) Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci 119:19–24. doi:10.3109/03009734.2013.856970

    Article  PubMed Central  PubMed  Google Scholar 

  50. Zhi Q, Zhu J, Guo X, He S, Xue X, Zhou J et al (2013) Metastasis-related miR-185 is a potential prognostic biomarker for hepatocellular carcinoma in early stage. Biomed Pharmacother 67:393–398. doi:10.1016/j.biopha.2013.03.022

    Article  CAS  PubMed  Google Scholar 

  51. Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L (2013) Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res 32:21

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs. Cell 136:629–641. doi:10.1016/j.cell.2009.02.006

    Article  CAS  PubMed  Google Scholar 

  53. Moran VA, Perera RJ, Khalil AM (2012) Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 40:6391–6400. doi:10.1093/nar/gks296

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Rinn JL, Chang HY (2012) Genome regulation by long noncoding RNAs. Annu Rev Biochem 81:145–166. doi:10.1146/annurev-biochem-051410-092902

    Article  CAS  PubMed  Google Scholar 

  55. Fitzgerald KA, Caffrey DR (2014) Long noncoding RNAs in innate and adaptive immunity. Curr Opin Immunol 26C:140–146. doi:10.1016/j.coi.2013.12.001

    Article  Google Scholar 

  56. Zhao J, Lawless MW (2013) Long noncoding RNAs and their role in the liver cancer axis. Nat Rev Gastroenterol Hepatol. doi:10.1038/nrgastro.2013.87-c1

    PubMed  Google Scholar 

  57. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM et al (2007) Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132:330–342

    Article  CAS  PubMed  Google Scholar 

  58. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T et al (2011) Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 71:6320–6326

    Article  CAS  PubMed  Google Scholar 

  59. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-Iail R, Hochberg A et al (2007) The H19 non-coding RNA is essential for human tumour growth. PLoS One 2:e845

    Article  PubMed Central  PubMed  Google Scholar 

  60. Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A et al (2012) Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS One 7:e49462. doi:10.1371/journal.pone.0049462

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX et al (2011) Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumour growth through enhancer of zeste homolog 2 in humans. Hepatology 54:1679–1689. doi:10.1002/hep.24563

    Article  CAS  PubMed  Google Scholar 

  62. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F et al (2011) Overexpression of long non-coding RNA HOTAIR predicts tumour recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 18:1243–1250. doi:10.1245/s10434-011-1581-y

    Article  PubMed  Google Scholar 

  63. Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang Y, Tang GN et al (2013) Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology 57:1882–1892. doi:10.1002/hep.26195

    Article  CAS  PubMed  Google Scholar 

  64. Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G et al (2012) Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology 56:2231–2241. doi:10.1002/hep.25895

    Article  CAS  PubMed  Google Scholar 

  65. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F et al (2012) Long non-coding RNA MALAT-1 overexpression predicts tumour recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 29:1810–1816. doi:10.1007/s12032-011-0004-z

    Article  CAS  PubMed  Google Scholar 

  66. Geng YJ, Xie SL, Li Q, Ma J, Wang GY (2011) Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 39:2119–2128

    Article  CAS  PubMed  Google Scholar 

  67. Zhang L, Yang F, Yuan JH, Yuan SX, Zhou WP, Huo XS et al (2013) Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis 34:577–586. doi:10.1093/carcin/bgs381

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Medicine, School of Medicine and Medical Science, University College Dublin, Catherine McAuley Centre, Mater Misericordiae University Hospital, Dublin 7, Ireland

    Jun Zhao & Matthew W. Lawless

Authors
  1. Jun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew W. Lawless
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew W. Lawless .

Editor information

Editors and Affiliations

  1. Respiratory Research, Department of Medicine, Royal College of Surgeon in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland

    Catherine M. Greene

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zhao, J., Lawless, M.W. (2015). ncRNA as Diagnostics and Prognostics for Hepatocellular Carcinoma. In: Greene, C. (eds) MicroRNAs and Other Non-Coding RNAs in Inflammation. Progress in Inflammation Research. Springer, Cham. https://doi.org/10.1007/978-3-319-13689-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13689-9_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-13688-2

  • Online ISBN: 978-3-319-13689-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation